| | ☑特定对象调研□分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访□业绩说明会 | | 动类别 | □新闻发布会□路演活动 | | | □ 现场参观 | | | □其他（请文字说明其他活动内容） | | 参与单位名称 | 泰康资产 陈佳艺、肖锐 | | 及人员姓名 | 天风证券 唐婕、刘思远 | | | 远信资本 谢振东、黄垲锐 | | 时间 | 2025 年 6 月 4 日 | | 地点 | 公司会议室 | | 上市公司接待 | 1. 董事、副总经理、董事会秘书亓轶群 | | | 2. 战略与投资部经理 王亚丽 | | 人员姓名 | 3.投资者关系 张瑾 | | | 本次活动主要交流内容如下： | | | 1. 请介绍下公司核心产品情况及美国关税的影响 | | | （1）百菌清：作为公司重要的杀菌剂产品之一，在全球市场具 | | | 有稳定的需求。市场对百菌清的采购节奏有所变化，公司及时 | | | 调整销售策略，优化库存管理，实现百菌清销售额较往年保持 | | 投资者关系活 | | | 动主要内容介 | 平稳。 | | 绍 | （2）嘧菌酯：是公司杀菌剂产品矩阵中的明星产 ...

2024年，淡水河谷铁矿石实际产量为32767万吨，同比增加2%，超出年初设定的产量指导区间（31000万~32000万吨），处于最新上调后的产量指导区间 （32300万~33000万吨）。2025年，淡水河谷设定的产量指导区间为32500~33500万吨，较2024年略有提升。2024年，淡水河谷铁矿石项目的资本支出为 39.43亿美元，同比增加5%，显示其在扩产方面处于持续投入状态。 产能激增 考虑到淡水河谷与力拓采用国际通行的自然年度为财年周期（每年1月1日至12月31日），而必和必拓及FMG采用的是澳大利亚财年（7月1日至次年6月30 日），本文对四大矿山的产量数据及产能规划按财年口径分别进行统计与对比。2024年，淡水河谷与力拓这两大矿山实际产量合计为65565万吨；2025年， 其指导产量区间中值为66050万吨，仅同比增加485万吨。然而，基于两家公司季报披露的数据与项目建设进度进行估算，可以发现，2025年，其计划新增产 能合计约达4005万吨，新增产能远超指导产量的增幅。相比之下，必和必拓与FMG在2024财年（2023年7月至2024年6月）合计产量为45376万吨。2025财 年，两公司 ...

【DT新材料】 获悉，5月30日， 中简科技 发布公告，公司拟以自有资金投资建设高性能碳纤维产品项目， 总投资金额为14.02亿元，项目建设时间预 计36个月，项目建设规模为年产2000吨高性能碳纤维（涵盖T700级以上的高强型碳纤维）及配套产品项目，扩大聚丙烯腈原丝、碳纤维及碳纤维织物 的生产规模，增加高性能碳纤维的供应量 。 扩产原因主要是，随着下游应用领域的持续拓展和市场需求的快速增长，该公司现有碳纤维产能已难以满足客户持续需求，制约了其在技术创新、质量 提升和应用开发等方面的优势发挥，该公司亟需通过产能扩张来提升市场响应速度和供应保障能力。 中简科技目前主力产品为ZT7（性能高于T700级）和ZT9（性能对应T1000/T1100级）系列碳纤维产品， ZT7系列一、二期产能合计420吨，三期项目 （3条200吨ZT9系列）已经投产，且正在朝设计产能爬坡 。本次项目属于公司规划的四期项目，新建产能规模已经超过公司现有产能。 其中，核心产品ZT7系列碳纤维已批量供应军用战机、导弹卫星等尖端装备。此外， 公司正攻坚C919/C929预浸料国产化，技术指标直指日本东丽 TORAYCA®系列。若成功替代进口，单 ...

内容概要：乙烯-醋酸乙烯共聚物（EVA）是一种由乙烯和醋酸乙烯经共聚反应制得的复合材料，是继 高密度聚乙烯（HDPE）、低密度聚乙烯（LDPE）和线性低密度聚乙烯（LLDPE）之后的第四大乙烯 系列聚合物。近年来，在下游需求和进口替代双向推动下，我国乙烯-醋酸乙烯共聚物（EVA）产量不 断增长。据统计，2024年我国乙烯-醋酸乙烯共聚物（EVA）产量已从2019年的75.6万吨上升至238.35万 吨，年均复合增长率达33.25%。不过，由于下游需求放缓，其产量增速也自2023年起逐渐放缓，2024 年同比增幅回落至10.68%。 关键词：产业链；乙烯-醋酸乙烯共聚物（EVA）产能；乙烯-醋酸乙烯共聚物（EVA）产量；进出口 量；重点企业；发展趋势 一、行业概况 乙烯-醋酸乙烯共聚物（EVA），是一种通用高分子聚合物，由乙烯和醋酸乙烯经共聚反应制得，分子 式是 (C2H4)x.(C4H6O2)y，是继高密度聚乙烯（HDPE）、低密度聚乙烯（LDPE）和线性低密度聚乙烯 （LLDPE）之后的第四大乙烯系列聚合物。从生产工艺看，目前我国EVA生产工艺包括管式法和釜式 法两种。其中管式法具有单线产能及反应转化率较高 ...

内容概要：芳纶纸，又名聚芳酰胺纤维纸，是以芳纶短切纤维和芳纶沉析纤维为主要原材料，经纤维分 散，通过湿法成形技术制备成纸，再经高温整饰制得的一种高性能新材料。近年来，随着新能源汽车、 风力发电、光伏发电、5G 通信、算力等芳纶纸新兴应用领域的出现，芳纶纸的市场需求逐步扩大。数 据显示，2024年我国芳纶纸市场消费量已从2017年2742吨增长至6684吨。未来，随着高速列车、地铁轻 轨及电网改造的进程加快，机车大功率牵引变压器、电机及智能电网新型输变电设备需求将会大幅度增 长，变压器等设备用芳纶绝缘纸的市场将迎来新的增长点，同时，国产大飞机对蜂窝芯材芳纶纸的需求 也将带动国内芳纶纸行业的发展。根据市场预测，2028年我国芳纶纸市场消费总量有望达到12357吨。 相关上市企业：民士达（833394）；泰和新材（002254）等 相关企业：美国杜邦公司（DuPont）；赣州龙邦材料科技有限公司；超美斯新材料股份有限公司；株 洲时代华先材料科技有限公司；山东聚芳新材料股份有限公司；广东华创化工有限公司；中航复合材料 有限责任公司；四川辉腾科技股份有限公司等 关键词：产业链；绝缘材料产量；C919飞机产能规划；芳纶纸 ...

Sociedad Química y Minera de Chile (SQM) Q1 2025 Earnings Call May 28, 2025 12:00 PM ET Company Participants Isabel Bendeck - Investor RelationsRicardo Ramos - CEO & General ManagerBen Isaacson - Managing Director - Equity ResearchGerardo Illanes - VP - Services & FinanceJoel Jackson - Managing DirectorFelipe Smith - Senior Commercial VP - LithiumCarlos Díaz Ortiz - General Manager - Lithium Potassium DivisionAndres Fontannaz - Commercial Vice PresidentAlejandro Demichelis - Managing Director - Equity Resea ...

REX American Resources (REX) Q1 2026 Earnings Call May 28, 2025 11:00 AM ET Company Participants Douglas Bruggeman - VP of Finance, CFO & TreasurerStuart Rose - Executive Chairman & Head of Corporate DevelopmentZafar Rizvi - CEO, President & Director Conference Call Participants Peter Gastreich - Managing Director - Energy and Sustainability Analyst Operator Greetings, and welcome to the REX American Resources Corporation's First Quarter twenty twenty five Earnings Call. At this time, all participants are i ...

Financial Data and Key Metrics Changes - In Q1 2025, ethanol sales volumes were 70.9 million gallons, down from 74.5 million gallons in Q1 2024, with an average selling price of $1.76 per gallon [10] - Gross profit for Q1 2025 was $14.3 million, slightly down from $14.5 million in Q1 2024, primarily due to lower sales prices for dry distiller grains [11] - Net income attributable to REX shareholders was $8.7 million or $0.51 per diluted share, compared to $10.2 million or $0.58 per diluted share in Q1 2024 [12] - Cash, cash equivalents, and short-term investments at the end of Q1 were $315.9 million, reflecting ongoing capital investments and share repurchases [12] Business Line Data and Key Metrics Changes - Dry distiller grain sales volumes were approximately 153,000 tons with an average selling price of $145.65 per ton [10] - Modified distillery grain volumes totaled approximately 22,000 tons with an average selling price of $73.44 per ton [11] - Corn oil sales volumes were approximately 21.4 million pounds during the quarter with an average selling price of $0.46 per pound [11] Market Data and Key Metrics Changes - U.S. ethanol exports through March 2025 were nearly 19% higher than the same period in 2024, with March 2025 exports up 23% compared to March 2024 [16][17] - The company anticipates stable performance in Q2 2025, expecting another profitable result [16] Company Strategy and Development Direction - The company is focused on organic growth initiatives, including carbon capture and expansion of ethanol production capacity, with a combined budget range of $220 million to $230 million for both projects [5][9] - REX continues to evaluate potential acquisition opportunities that meet strict operational and financial criteria [5] - The company is committed to delivering consistent value to shareholders through share buybacks, having repurchased approximately 822,000 shares for $32.7 million in Q1 2025 [6][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate uncertain regulatory and market conditions, highlighting the strength of the balance sheet [4] - The company is closely monitoring potential changes to the Inflation Reduction Act and other regulatory developments that could impact future economic decisions [8] - Management remains optimistic about the ethanol sector's favorable market conditions and expects record corn production to boost profits for the rest of the year [29] Other Important Information - The company has maintained a strong financial position with no bank debt [13] - The ongoing technical review of the ethanol facility expansion is expected to enhance long-term operational efficiencies [7] Q&A Session Summary Question: What drives REX's ability to consistently deliver performance? - Management attributed consistent profitability to strong leadership, effective monitoring of market conditions, and a dedicated team [20][22] Question: What specific deregulation measures would help smooth the runway? - Management noted that regulatory developments are currently in limbo and emphasized the importance of monitoring changes closely [24][27] Question: Thoughts on industry fundamentals and ethanol margins? - Management expects positive trends in ethanol margins due to strong corn production and favorable export conditions, while also monitoring natural gas prices closely [29]

Core Insights - The company is facing a dangerous expansion paradox with significant fixed asset investments of 1.894 billion yuan and ambitious capacity expansion plans, while experiencing a low capacity utilization rate of only 26.15% and actual drug sales revenue of 145 million yuan [1][2] Group 1: Sales Performance - The company's main products are underperforming, with a drastic decline in sales revenue. The projected sales for three key drugs were expected to reach between 1.435 billion to 1.762 billion yuan by 2025, but actual revenue for 2024 is only 145 million yuan, less than one-tenth of the optimistic forecast [2] - The drug Junmaikang (similar to Adalimumab) saw a 70% drop in shipment volume from approximately 166,900 units in 2023 to 48,800 units in 2024, facing intense competition and high costs [2] - The drug Mailishu (similar to Dexamethasone) also fell short of expectations, with actual sales of only 84,400 units and revenue of 42.09 million yuan in 2023, compared to a forecast of at least 300,000 units and 180 million yuan [2] - The drug Maiweijian (similar to Dexamethasone) was only approved by the end of March 2024, with shipments of just 12,530 units, limited by fewer approved indications and a lengthy market access process [2] Group 2: Capacity Expansion and Financial Strain - Despite poor sales performance, the company has aggressively expanded its production capacity, with fixed assets increasing by 165.49% to 1.653 billion yuan by the end of 2024, and total fixed assets and construction in progress reaching 1.894 billion yuan, accounting for 44.31% of total assets [3] - The actual capacity utilization rate is only 26.15%, with a production and sales rate of 81.08%. The company anticipates annual fixed asset depreciation costs of approximately 130 million yuan, nearly equal to its total drug sales revenue for 2024 [3] Group 3: Debt and Cash Flow Challenges - The company is under significant financial pressure, with short-term borrowings and long-term borrowings due within one year totaling 1.035 billion yuan by the end of 2024, leading to a debt-to-asset ratio of 63.61% and a negative operating cash flow of -956 million yuan [4] - The company is relying on two strategies to address its financial challenges: completing an H-share IPO for capital infusion and hoping for future revenue from unlisted pipelines to cover debts [4] Group 4: Leadership and IPO Uncertainty - The chairman and general manager of the company is under investigation for suspected insider trading, which has caused a significant drop in stock price and raised concerns about the impact on the H-share IPO process [5] - Although the company claims the investigation does not affect daily operations or the IPO plan, the Hong Kong Stock Exchange has strict scrutiny over management stability and integrity, which could delay the IPO process significantly [6] - The company submitted its prospectus for the Hong Kong IPO on January 6, and must complete the hearing or listing within six months, or the prospectus will become invalid, adding pressure to resolve the investigation quickly [6]

业绩方面，一季报显示，公司当季实现营业收入789.28亿元，同比增长5.55%；归母净利润约101.67亿 元，同比增长62.39%；经营现金流净额为125.3亿元，同比增长53.33%。 分拆核心资产赴港上市 中国矿业巨头紫金矿业（601899）(601899.SH)拟分拆境外金矿赴港上市。 5月26日，紫金矿业公告称，公司拟将其控股子公司紫金黄金国际分拆至香港联交所主板上市，并计划 在上市前将下属多座境外黄金矿山资产重组整合至紫金黄金国际旗下。 值得注意的是，本次拟分拆上市资产由八座位于南美、中亚、非洲和大洋洲的世界级大型黄金矿山组 成。 本次分拆完成后，紫金矿业股权结构不会发生变化，仍将维持对紫金黄金国际的控制权。紫金黄金国际 将进一步深耕境外市场业务，持续推进全球黄金资源开发。 近年，公司加速推进全球产能扩张，2025年矿产金产能计划扩张至85吨，增幅达16%。至2028年，目标 进一步上调至100—110吨，相当于再造一个"山东黄金（600547）"。 不过，紫金矿业在风险提示中表示，上述八座黄金矿山资产尚未全部完成注入子公司紫金黄金国际，若 后续八座黄金矿山资产注入进展未达预期，可能对本次交易带来 ...